Rosuvastatin limits the activation of hepatic stellate cells in diet-induced obese mice

Hepatology Research

Volumn 47, Issue 9, 2017, Pages 928-940

  Marinho, Thatiany de Souza ^a   Kawasaki, Adriana ^a   Bryntesson, Marcus ^b   Souza Mello, Vanessa ^a   Barbosa da Silva, Sandra ^a   Aguila, Marcia B ^a   Mandarim de Lacerda, Carlos A ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

beta oxidation; hepatic stellate cells; lipogenesis; NAFLD; statin; stereology

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; CHOLESTEROL; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSUVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET INDUCED OBESITY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GLUCOSE INTOLERANCE; HEPATIC STELLATE CELL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 85000789286     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12821     Document Type: Article

References (50)

1. Thompson AI, Conroy KP, Henderson NC. Hepatic stellate cells: central modulators of hepatic carcinogenesis. BMC Gastroenterol 2015; 15: 63.
2. Chen A, Tang Y, Davis V et al. Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology 2013; 57: 2202–2212.
3. Lin L, Teng M, Zhao YJ et al. Long-term cost-effectiveness of statin treatment for primary prevention of cardiovascular disease in the elderly. Cardiovasc Drugs Ther 2015; 29: 187–197.
4. de Keyser CE, Koehler EM, Schouten JN et al. Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. Dig Liver Dis 2014; 46: 720–725.
5. Fraulob JC, Souza-Mello V, Aguila MB, Mandarim-de-Lacerda CA. Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clin Sci (Lond) 2012; 123: 259–270.
6. Dongiovanni P, Petta S, Mannisto V et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705–712.
7. Malaguarnera M, Vacante M, Russo C et al. Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: rosuvastatin reduces NAFLD in HCV patients. Hepat Mon 2011; 11: 92–98.
8. Okada Y, Yamaguchi K, Nakajima T et al. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. Liver Int 2013; 33: 301–311.
9. Simic I, Reiner Z. Adverse effects of statins – myths and reality. Curr Pharm Des 2015; 21: 1220–1226.
10. Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015; 58: 1109–1117.
11. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735–742.
12. Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014; 8: S47–S57.
13. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656–665.
14. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76 A rodent diet. J Nutr 1993; 123: 1939–1951.
15. Aguila MB, Pinheiro AR, Parente LB, Mandarim-de-Lacerda CA. Dietary effect of different high-fat diet on rat liver stereology. Liver Int 2003; 23: 363–370.
16. Mandarim-de-Lacerda CA. Stereological tools in biomedical research. Ann Brazil Acad Sci 2003; 75: 469–486.
17. Catta-Preta M, Mendonca LS, Fraulob-Aquino J, Aguila MB, Mandarim-de-Lacerda CA. A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies. Virchows Arch 2011; 459: 477–485.
18. Mihos CG, Pineda AM, Santana O. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res 2014; 88: 12–19.
19. Bezerra DG, Mandarim-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats. Clin Sci (Lond) 2005; 108: 349–355.
20. Bezerra DG, Andrade LM, Cruz FO, Mandarim-de-Lacerda CA. Atorvastatin attenuates cardiomyocyte loss in adult rats from protein-restricted dams. J Card Fail 2008; 14: 151–160.
21. McKenney JM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm 2005; 62: 1033–1047.
22. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011; 215: 1–8.
23. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380: 565–571.
24. Chan DC, Pang J, Watts GF. Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10? Curr Atheroscler Rep 2015; 17: 472.
25. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003; 1: 495–505.
26. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004; 24: 584–591.
27. Ramachandran P, Iredale JP, Fallowfield JA. Resolution of liver fibrosis: basic mechanisms and clinical relevance. Semin Liver Dis 2015; 35: 119–131.
28. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655–1669.
29. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011; 106: 71–77.
30. Yang JI, Yoon JH, Bang YJ et al. Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2010; 298: G126–G132.
31. Trebicka J, Hennenberg M, Odenthal M et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010; 53: 702–712.
32. Rombouts K, Kisanga E, Hellemans K, Wielant A, Schuppan D, Geerts A. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 2003; 38: 564–572.
33. Takahashi Y, Soejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2012; 18: 2300–2308.
34. Kanuri G, Bergheim I. In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci 2013; 14: 11963–11980.
35. Dixon LJ, Flask CA, Papouchado BG, Feldstein AE, Nagy LE. Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS One 2013; 8: e56100.
36. Schultz A, Barbosa-da-Silva S, Aguila MB, Mandarim-de-Lacerda CA. Differences and similarities in hepatic lipogenesis, gluconeogenesis and oxidative imbalance in mice fed diets rich in fructose or sucrose. Food Funct 2015; 6: 1684–1691.
37. Barbosa-da-Silva S, Souza-Mello V, Magliano DC, Marinho Tde S, Aguila MB, Mandarim-de-Lacerda CA. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice. Life Sci 2015; 127: 73–81.
38. Riche DM, Fleming JW, Malinowski SS, Black CA, Miller KH, Wofford MR. Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. Ann Pharmacother 2014; 48: 137–141.
39. Landrier JF, Thomas C, Grober J et al. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-α-dependent. J Biol Chem 2004; 279: 45 512–8.
40. Rodriguez-Calvo R, Barroso E, Serrano L et al. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology 2009; 49: 106–115.
41. Barbosa-da-Silva S, da Silva NC, Aguila MB, Mandarim-de-Lacerda CA. Liver damage is not reversed during the lean period in diet-induced weight cycling in mice. Hepatol Res 2013; 44: 450–459.
42. Souza-Mello V, Gregorio BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB, Mandarim-de-Lacerda CA. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond) 2010; 119: 239–250.
43. Penna-de-Carvalho A, Graus-Nunes F, Rabelo-Andrade J, Mandarim-de-Lacerda CA, Souza-Mello V. Enhanced pan-peroxisome proliferator-activated receptor gene and protein expression in adipose tissue of diet-induced obese mice treated with telmisartan. Exp Physiol 2014; 99: 1663–1678.
44. Zhang X, Fitzsimmons RL, Cleland LG et al. CD36/fatty acid translocase in rats: distribution, isolation from hepatocytes, and comparison with the scavenger receptor SR-B1. Lab Invest 2003; 83: 317–332.
45. Fajas L, Schoonjans K, Gelman L et al. Regulation of peroxisome proliferator-activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol 1999; 19: 5495–5503.
46. −/−) mice. Lipids 2003; 38: 519–523.
47. Hazra S, Miyahara T, Rippe RA, Tsukamoto H. PPARγ and hepatic stellate cells. Comp Hepatol 2004; 3(Suppl 1): S7.
48. Ramani K, Tomasi ML. Transcriptional regulation of methionine adenosyltransferase 2 A by peroxisome proliferator-activated receptors in rat hepatic stellate cells. Hepatology 2012; 55: 1942–1953.
49. Da Silva Morais A, Abarca-Quinones J, Horsmans Y, Starkel P, Leclercq IA. Peroxisome proliferated-activated receptor γ ligand, pioglitazone, does not prevent hepatic fibrosis in mice. Int J Mol Med 2007; 19: 105–112.
50. Gao M, Ma Y, Alsaggar M, Liu D. Dual outcomes of rosiglitazone treatment on fatty liver. Am Ass Pharmac Sci J 2016; 18: 1023–1031.